Ruxolitinib for the treatment of SARS-CoV-2 induced acute respiratory distress syndrome (ARDS)

Leukemia. 2020 Aug;34(8):2276-2278. doi: 10.1038/s41375-020-0907-9. Epub 2020 Jun 17.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Betacoronavirus
  • COVID-19
  • Coronavirus Infections*
  • Humans
  • Janus Kinase 1
  • Nitriles
  • Pandemics*
  • Pneumonia, Viral*
  • Pyrazoles
  • Pyrimidines
  • Respiratory Distress Syndrome*
  • SARS-CoV-2

Substances

  • Nitriles
  • Pyrazoles
  • Pyrimidines
  • ruxolitinib
  • Janus Kinase 1